- EyePoint is on a steeply upward sloping growth path with two relatively new treatments and a third one on the way.
- However, the coronavirus pandemic is hobbling the growth path of one of these (DEXYCU), but the company has intervened to save cash.
- We think establishing an initial position at these levels is likely to pay off, given the steep declines the shares already experienced.
- We can’t exclude further declines, given what is happening on the ground, but like the risk-reward position here.
EyePoint Still Has A Very Promising Future
April 14th, 2020 · No Comments